Pancreas Cancer study: Tumor Treating Fields
Official title Stereotactic Body Radiation and Tumor Treating Fields for Locally Advanced Pancreas Cancer
ClinicalTrials.gov ID: NCT05679674
What this study is testing
- What it's testing
- This study is testing whether chemotherapy followed by stereotactic ablative body radiation therapy and tumor treating fields can slow tumor growth in people with locally advanced pancreas cancer.
- Who it's for
- You may be able to join if you have locally advanced pancreatic cancer.
- What's involved
- You will get chemotherapy, then radiation therapy once a day for five days, and you will wear a tumor treating fields device at home for at least 18 hours each day.
- Time commitment
- The study lasts until the tumor grows or side effects become severe, with daily radiation visits for five days and ongoing home use of the device.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Histologically or cytologically confirmed locally advanced adenocarcinoma of the pancreas.
- Regional lymph node involvement is permitted if able to be treated with radiation therapy.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- At least 3 months of prior FOLFIRINOX, modified FOLFIRINOX, and/or gemcitabine/nab-paclitaxel delivered for pancreas cancer without evidence of...
- Carbohydrate antigen 19-9 (CA 19-9) ≤500 U/mL on most recent assessment prior to study enrollment.
You likely can't join if
- Distant metastasis from pancreas cancer.
- Contraindication to having a magnetic resonance imaging (MRI) scan.
- Prior abdominal radiation therapy.
- Malignancy treated with curative intent and with no known active disease for at least 3 years before enrollment on this study.
- Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.
- Adequately treated carcinoma in situ without evidence of disease (i.e., cervical carcinoma in situ; superficial bladder cancer).
See the full eligibility criteria
- Histologically or cytologically confirmed locally advanced adenocarcinoma of the pancreas. Locally advanced pancreas cancer as per National Comprehensive Cancer Network (NCCN) Guidelines.
- Regional lymph node involvement is permitted if able to be treated with radiation therapy.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- At least 3 months of prior FOLFIRINOX, modified FOLFIRINOX, and/or gemcitabine/nab-paclitaxel delivered for pancreas cancer without evidence of distant progression on restaging radiographic studies.
- Carbohydrate antigen 19-9 (CA 19-9) ≤500 U/mL on most recent assessment prior to study enrollment.
- Adequate normal organ and marrow function as defined below: i. Hemoglobin ≥8.0 g/dL that may be achieved with transfusion ii. Absolute neutrophil count (ANC) ≥1500 per mm\^3 iii. Platelet count ≥60,000 per mm\^3 iv.
- People of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation.
- Able to operate the tumor treating field (NovoTTF-100L) system independently or with assistance.
- All participants must sign written informed consent.
- Distant metastasis from pancreas cancer.
- Contraindication to having a magnetic resonance imaging (MRI) scan.
- Prior abdominal radiation therapy.
- Malignancy treated with curative intent and with no known active disease for at least 3 years before enrollment on this study.
- Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.
- Adequately treated carcinoma in situ without evidence of disease (i.e., cervical carcinoma in situ; superficial bladder cancer).
- Any unresolved toxicity (Common Terminology Criteria for Adverse Events version 5.0 \> grade 2) from previous anti-cancer therapy.
- History of inflammatory bowel disease (i.e., Crohn's disease, ulcerative colitis).
- Any condition in the opinion of the investigator that would interfere with evaluation of study treatment or interpretation of patient safety or study results.
- Participants who are pregnant or breastfeeding. Patients with an electrical implantable device in the torso.
- History of significant uncontrolled cardiovascular disease. Significant cardiac disease includes second/third degree heart block; significant ischemic heart disease; poorly controlled hypertension
- History of arrhythmia that is symptomatic or requires treatment. Patients with atrial fibrillation or flutter controlled by medication are not excluded from participation in the trial.
- Known allergy to medical adhesives or conductive hydrogel [gel used on electrocardiogram (ECG) stickers or transcutaneous electrical nerve stimulation (TENS) electrodes].
The study team makes the final eligibility decision.
Where it is enrolling
- Miami, Florida, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Miami, Florida, United States. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.